Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the
“Company”), a leading health sciences company, welcomes Kathryn M.
Henry and David Vanderveen as independent directors to the
Company’s Board of Directors.
“We are excited to welcome Kathryn and David to
Prenetics’ Board of Directors at this pivotal juncture,” said Danny
Yeung, CEO of Prenetics. “Their unparalleled expertise in consumer
and health sectors, combined with their proven leadership in
driving global expansion and operational excellence, will
significantly enhance shareholder value as we expand into consumer
health and wellness.”
"I am thrilled to join Prenetics at such a
pivotal moment," said Kathryn Henry. "I look forward to
contributing to the company's growth and leveraging my experience
to help drive its expansion into the consumer health and wellness
sector."
"I am incredibly impressed by Prenetics'
comprehensive approach to consumer health and wellness," said David
Vanderveen. "I am confident our strategy will significantly disrupt
the market and look forward to leveraging my experience in helping
Prenetics achieve its ambitious goals."
Kathyrn M. Henry
Ms. Henry’s extensive experience in leading
global information and technology operations, especially in
consumer retail and technology sectors, aligns perfectly with
Prenetics' strategic positioning into consumer health and
wellness.
Ms. Henry is currently an independent director
at Lululemon, where she has been a board member for more than 8
years and serves as a member of the Audit & Compensation
Committee.
Ms. Henry previously served as Chief Information
Officer, Logistics & Distribution at Lululemon from 2010 to
2014, where she oversaw all global information and technology
operations for the company.
Prior to joining Lululemon in 2010, Ms. Henry
worked at Gap, Inc., where she served as Vice President and Chief
Information Officer of International IT and Gap North America.
David Vanderveen
Mr. Vanderveen’s extensive experience in the
beverage, nutrition, and technology sectors, along with his proven
track record, aligns seamlessly with Prenetics’ strategic
positioning into consumer health and wellness.
Mr. Vanderveen has had a successful 30-year
track record in beverage, nutrition, and technology, at both
private and public companies. From 2022 until recently, he was CEO
of Nirvana Water Sciences, where he developed a team of functional
beverage and supplement experts to transform the brand, product
portfolio, go-to-market strategy, and execution of the
business.
From 2002 to 2015, Mr. Vanderveen was the
founder and CEO of XS Worldwide, a company with a portfolio of
energy drinks and nutrition products. XS partnered with Amway
Corporation, reaching annual sales over $400 million, in more than
60 countries. XS was sold to Amway in 2015, where Mr. Vanderveen
served as Global General Manager for XS, achieving maximum earn-out
through 2018.
About Prenetics
Prenetics (NASDAQ:PRE), a leading health
sciences company, is revolutionizing prevention, early detection,
and treatment. Our prevention arm, CircleDNA, uses whole exome
sequencing to offer the world's most comprehensive consumer DNA
test. Insighta, our $200 million joint venture with renowned
scientist Prof. Dennis Lo, underscores our unwavering commitment to
saving lives through pioneering multi-cancer early detection
technologies. Lastly, our treatment unit, ACT Genomics, has
achieved FDA clearance for comprehensive genomic profiling of solid
tumors through its ACTOnco platform. Each of Prenetics' units
synergistically enhances our global impact on health, truly
embodying our commitment to 'enhancing life through science’. To
learn more about Prenetics, please visit www.prenetics.com.
Forward-Looking Statements
This press release contains forward-looking
statements. These statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Statements that are not historical facts, including
statements about the Company's goals, targets, projections,
outlooks, beliefs, expectations, strategy, plans, objectives of
management for future operations of the Company, and growth
opportunities are forward-looking statements. In some cases,
forward-looking statements can be identified by words or phrases
such as "may," "will," "expect," "anticipate," "target," "aim,"
"estimate," "intend," "plan," "believe," "potential," "continue,"
"is/are likely to" or other similar expressions. Forward-looking
statements are based upon estimates and forecasts and reflect the
views, assumptions, expectations, and opinions of the Company,
which involve inherent risks and uncertainties, therefore they
should not be relied upon as being necessarily indicative of future
results. A number of factors could cause actual results to differ
materially from those contained in any forward-looking statement,
including but not limited to: the Company’s ability to further
develop and grow its business, including new products and services;
its ability to execute on its new business strategy in genomics,
precision oncology, and specifically, early detection for cancer;
the results of case control studies and/or clinical trials; and its
ability to identify and execute on M&A opportunities,
especially in precision oncology. In addition to the foregoing
factors, you should also carefully consider the other risks and
uncertainties described in the “Risk Factors” section of the
Company’s most recent registration statement and the prospectus
therein, and the other documents filed by the Company from time to
time with the U.S. Securities and Exchange Commission. All
information provided in this press release is as of the date of
this press release, and the Company does not undertake any duty to
update such information, except as required under applicable
law.
Investor Relations
Contact:investors@prenetics.comPRE@mzgroup.us
Prenetics Global (NASDAQ:PRE)
Historical Stock Chart
From Nov 2024 to Dec 2024
Prenetics Global (NASDAQ:PRE)
Historical Stock Chart
From Dec 2023 to Dec 2024